P

Pierrel SpA
MIL:PRL

Watchlist Manager
Pierrel SpA
MIL:PRL
Watchlist
Price: 1.745 EUR
Market Cap: 95.9m EUR
Have any thoughts about
Pierrel SpA?
Write Note

Pierrel SpA
Capital Expenditures

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Pierrel SpA
Capital Expenditures Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
P
Pierrel SpA
MIL:PRL
Capital Expenditures
-€11.2m
CAGR 3-Years
-37%
CAGR 5-Years
-60%
CAGR 10-Years
N/A
Newron Pharmaceuticals SpA
SIX:NWRN
Capital Expenditures
-€10k
CAGR 3-Years
31%
CAGR 5-Years
32%
CAGR 10-Years
N/A
Recordati Industria Chimica e Farmaceutica SpA
MIL:REC
Capital Expenditures
-€56.8m
CAGR 3-Years
34%
CAGR 5-Years
-22%
CAGR 10-Years
-12%
Friulchem SpA
MIL:FCM
Capital Expenditures
-€6.9m
CAGR 3-Years
-74%
CAGR 5-Years
-52%
CAGR 10-Years
N/A
Shedir Pharma Srl Unipersonale
MIL:SHE
Capital Expenditures
-€3.6m
CAGR 3-Years
-99%
CAGR 5-Years
-19%
CAGR 10-Years
N/A
No Stocks Found

Pierrel SpA
Glance View

Market Cap
95.9m EUR
Industry
Pharmaceuticals

Pierrel SpA engages in the development, manufacturing, and marketing of medical therapies for the pharmaceutical, bio-pharmaceutical, and life science industries. The company is headquartered in Capua, Caserta. The company went IPO on 2006-05-23. The firm specializes in the pharmaceutical research, development and the manufacture of medicines. The company operates through three segments. The Contract Manufacturing segment covers research and development of various types of drugs, such as Tube vials, bottles, ampoules, drops, sprays, tablets and gels. The company manufactures the drugs in the production facility in Capua, which consists of warehouses, chemical and microbiological laboratories, offices and utilities buildings. The Pharma segment is active in the development, registration and licensing of new drugs and medical devices. The Tech-driven Contract Research & Development Organization segment provides research of existing drugs for the treatment of rare diseases, among others.

PRL Intrinsic Value
1.849 EUR
Undervaluation 6%
Intrinsic Value
Price
P

See Also

What is Pierrel SpA's Capital Expenditures?
Capital Expenditures
-11.2m EUR

Based on the financial report for Jun 30, 2023, Pierrel SpA's Capital Expenditures amounts to -11.2m EUR.

What is Pierrel SpA's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
-60%

Over the last year, the Capital Expenditures growth was 28%. The average annual Capital Expenditures growth rates for Pierrel SpA have been -37% over the past three years , -60% over the past five years .

Back to Top